Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).
Ballantyne CM, Banach M, Bays HE, Catapano AL, Laufs U, Stroes ESG, Robinson P, Lei L, Ray KK. Ballantyne CM, et al. Among authors: catapano al. Am J Cardiol. 2022 Jul 1;174:1-11. doi: 10.1016/j.amjcard.2022.03.020. Epub 2022 Apr 26. Am J Cardiol. 2022. PMID: 35483979 Free article. Clinical Trial.
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Polis AB, et al. Among authors: catapano al. Metab Syndr Relat Disord. 2009 Dec;7(6):601-10. doi: 10.1089/met.2009.0009. Metab Syndr Relat Disord. 2009. PMID: 19929597 Clinical Trial.
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.
Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, Rosenberg E, Tershakovec AM. Davidson MH, et al. Among authors: catapano al. J Clin Lipidol. 2008 Dec;2(6):436-46. doi: 10.1016/j.jacl.2008.10.003. Epub 2008 Oct 22. J Clin Lipidol. 2008. PMID: 21291777
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel. Chapman MJ, et al. Among authors: catapano al. Eur Heart J. 2011 Jun;32(11):1345-61. doi: 10.1093/eurheartj/ehr112. Epub 2011 Apr 29. Eur Heart J. 2011. PMID: 21531743 Free PMC article. Review.
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, Catapano AL, Reiner Ž, Lüscher TF. Ray KK, et al. Among authors: catapano al. Eur Heart J. 2014 Apr;35(15):960-8. doi: 10.1093/eurheartj/ehu107. Epub 2014 Mar 17. Eur Heart J. 2014. PMID: 24639424
606 results